Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Stock Information | RedChip

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Listen to this Section


$12.08
-0.3900 ( -3.13% ) 61.6K

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Market Data


Open


$12.08

Previous close


$12.47

Volume


61.6K

Market cap


$213.08M

Day range


$12.07 - $12.57

52 week range


$7.12 - $17.30

Insider Ownership Transactions

Total Amount Purchased: -811,250.00 | $ -9,799,900.00

Date Type Amount Purchased Purchaser
2024-05-29 Sale -25000.00 MOOS WALTER H
2024-05-29 Sale -25000.00 Ali-Jackson Kamil
2024-05-29 Sale -25000.00 Kotzin Brian L.
2024-05-29 Sale -25000.00 HANNAH ALISON L.
2024-05-29 Sale -25000.00 LAPOINTE ANTHONY GREGG
2024-05-29 Sale -25000.00 Wasman Jane
2024-03-29 Sale -187500.00 Rojkjaer Lisa
2024-03-01 Sale -93750.00 Furey Raymond J.
2024-03-01 Sale -300000.00 RODRIGUEZ RAUL R
2024-03-01 Sale -80000.00 Santos David A

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 79 Aug 06, 2024
8-k 8K-related 14 Aug 06, 2024
8-k 8K-related 14 Jun 27, 2024
8-k 8K-related 15 Jun 25, 2024
4 Insider transactions 1 May 29, 2024
4 Insider transactions 1 May 29, 2024
4 Insider transactions 1 May 29, 2024
4 Insider transactions 1 May 29, 2024
8-k 8K-related 13 May 29, 2024
4 Insider transactions 1 May 29, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.